Can IDYA sustain its Q4 earnings momentum?

**IDYA's ability to sustain its Q4 earnings momentum appears challenging based on several indicators.** Here's an analysis to support this view:

1. **Financial Performance in Q4**: IDEAYA Biosciences reported a net loss of $130.31 million for Q4 2024, with an EPS of -$0.52, missing estimated earnings by 10.64%. This indicates a significant financial strain during the period.

2. **Analyst Ratings and Estimates**: While there has been a 'Buy' consensus rating from analysts, recent earnings estimates have been adjusted downwards. For instance, Leerink Partners decreased Q2 2024 EPS estimates, and Wedbush boosted FY2024 EPS estimates but not Q4-specific estimates. This could suggest a cautious outlook regarding the sustainability of Q4 performance.
3. **Cash Position and Future Projections**: IDEAYA believes that its funds will be sufficient to fund operations into at least 2028. However, the company's financial results and business update for 2024 did not provide specific projections for sustaining momentum.
4. **Market Reaction and Performance**: Following the earnings release, the stock experienced a 1.16% increase on February 14, 2025, which may indicate a brief market optimism. However, this does not necessarily translate into sustained earnings momentum.

|code|Ticker|Name|Date|Percentage Change|market_code|
|---|---|---|---|---|---|
|IDYA|IDYA.O|IDEAYA Biosciences|20250214|1.1561|185|

In conclusion, while there is a slight positive market reaction, the overall indicators point towards challenges in sustaining the Q4 earnings momentum. The company's financial performance, analyst estimates, and lack of specific future projections suggest that IDYA may face difficulties in maintaining its earnings momentum.